Daewoong Pharma Receives Mexico Marketing Approval for Diabetes Drug Envlo, Expanding into Latin America for Overseas Sales Growth
Daewoong Pharma received marketing approval from the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) for its own-developed type 2 diabetes treatment Envlo (enavogliflozin) 0.3mg tablets.
Envlo is the 36th domestic new drug, an SGLT2 inhibitor, which has been sold in Korea since its domestic approval in 2022.
This approval marks the first entry into the Latin American market, and the company plans to establish an optimal marketing strategy and launch the product.
[AI Comprehensive Analysis]This Mexico marketing approval is a positive signal for overseas sales diversification, but short-term financial contribution is expected to be limited. In the long term, it is expected to contribute to securing growth momentum through expansion in Latin America.
KOSPI Filing Information
Filing: Major Management Matters Related to Investment Decision (Envlo 0.3mg Mexico Item Approval)